Intuitive Surgical (NasdaqGS:ISRG) Q4 2025 Earnings call January 22, 2026 04:30 PM ET Company ParticipantsTravis Steed - Managing Director of Equity Research in Medical TechnologyRick Wise - Managing DirectorJamie Samath - CFODavid Roman - Managing DirectorPatrick Wood - Managing DirectorDan Connally - VP of Investor RelationsDave Rosa - CEOConference Call ParticipantsRobbie Marcus - Senior Analyst of Medical Devices and ServicesLarry Biegelsen - Senior Medical Device Equity Research AnalystOperatorGood day ...

Financial Data and Key Metrics Changes - The company reported a 1% increase in volume but a 1% decrease in revenue due to business mix headwinds and coal pricing [9][14] - Operating income fell by 9% and earnings per share decreased by 7% year-over-year [9][10] - Fourth quarter expenses increased by $73 million, or 3%, excluding goodwill impairment charges [10][11] Business Line Data and Key Metrics Changes - Merchandise volume and revenue both decreased by 2%, with softness in chemicals and forest products [14][16] - Automotive volume was down 5% year-over-year, while fertilizer volume increased by 7% [15][16] - Intermodal revenue grew by 7% year-over-year on a 5% increase in volume, driven by new business wins [16] Market Data and Key Metrics Changes - The industrial chemicals market remains weak, affecting freight spending [14] - The housing market is expected to see a modest decline in starts, impacting commodity markets [18] - Domestic utility coal demand increased due to higher power demand and natural gas prices [16][19] Company Strategy and Development Direction - The company aims for low single-digit revenue growth in 2026, focusing on operational efficiency and cost discipline [21][22] - Capital expenditures are planned to be below $2.4 billion, emphasizing safety, reliability, and growth projects [22] - The company is preparing for potential opportunities arising from industry mergers while maintaining operational excellence [54][55] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a challenging year with subdued demand and limited growth opportunities [4][20] - There is no expectation of significant macroeconomic improvement in the near term, but the company is focused on internal initiatives to drive profitability [21][22] - Management is optimistic about the potential for growth in 2026, particularly in intermodal and domestic utility coal [19][20] Other Important Information - The company has identified over 100 cost-saving initiatives across various areas, including labor and non-labor spending [11][50] - The leadership team has been renewed to enhance operational effectiveness and drive value [5] Q&A Session All Questions and Answers Question: Inquiry about operating ratio improvement and pricing initiatives - Management indicated that the starting point for 2025's operating ratio excludes goodwill charges and emphasized ongoing pricing initiatives to improve yield in 2026 [28][29] Question: Clarification on guidance for operating margin improvement - Management noted that unique charges from 2025 would not recur in 2026, and they expect productivity improvements to drive margin expansion [32] Question: Discussion on revenue growth profile and mix effects - Management acknowledged that mix effects would impact revenue growth, with stronger growth expected in lower RPU segments [78][79] Question: Inquiry about coal revenue per unit and market conditions - Management clarified that coal RPU would be influenced by market mix and expected stabilization in the coming year [58][61] Question: Discussion on operational readiness for upcoming storms - Management assured that the network is in better condition compared to previous years and outlined preparedness measures for adverse weather [40][42] Question: Inquiry about the impact of industry mergers - Management emphasized the importance of operational excellence regardless of merger outcomes and expressed confidence in managing potential risks [54][55]

Financial Data and Key Metrics Changes - Revenue grew 21% year over year to $10.1 billion, with operating margins at 37% reflecting investments in R&D and manufacturing scale [8][16][29] - Proforma EPS increased 22%, marking the third consecutive year of growth above 20% [16] - Free cash flow rose to $2.5 billion, up from $1.3 billion in 2024 [16] Business Line Data and Key Metrics Changes - Total procedures grew 19%, with da Vinci procedures increasing 17% and Ion procedures growing 51% [5][16] - Single-port procedures grew 87%, while multi-port procedures increased 17% [5][11] - In Q4, da Vinci procedures in the U.S. increased 15% to over 2 million, while international procedures grew 23% [6][19] Market Data and Key Metrics Changes - U.S. procedures increased 16%, with da Vinci procedures growing 15% and Ion procedures growing 41% [17] - Internationally, da Vinci procedures grew 21%, with notable growth in Canada, India, Korea, and various European markets [20][21] - Japan's procedure growth was lower than expected due to capital placement challenges, with potential reimbursement changes anticipated in 2026 [21] Company Strategy and Development Direction - The company focuses on four strategic priorities: launching da Vinci 5, increasing adoption of focused procedures, building industrial scale, and enhancing digital tools [4][13] - Plans to expand into ambulatory surgery centers (ASCs) and enhance training and support for customers [19][56] - Continued investment in market access activities and local evidence generation to meet clinical and economic objectives [6][7] Management's Comments on Operating Environment and Future Outlook - Management believes the company is in the early stages of advancing minimally invasive care, with significant growth opportunities ahead [4][78] - Anticipated da Vinci procedure growth for 2026 is projected between 13%-15%, driven by general surgery and international procedures [36] - Expected gross profit margin for 2026 is projected to be between 67% and 68% of net revenue, with various factors impacting this guidance [37] Other Important Information - The company placed 1,721 da Vinci systems in 2025, including 870 da Vinci 5 systems [7][23] - The installed base of da Vinci systems increased by 12% to over 11,100 systems, with average system utilization rising by 4% [17][26] - The company plans to introduce additional products and features for da Vinci 5 in 2026 [10] Q&A Session Summary Question: FDA approvals for cardiac non-force feedback instruments - Management discussed the importance of supporting cardiac surgery and the foundational work being done, including training pathways and developing cardiac-specific instrumentation [41][42][44] Question: Advanced imaging features in the robotic ecosystem - Management explained that advanced imaging capabilities are being developed, which will add revenue streams and improve surgical outcomes [48][49] Question: ASC opportunity and key procedures - Management highlighted the growing ASC opportunity, focusing on high-quality clinical outcomes and the need for repeatable procedures [53][55] Question: Gross margin and operating expenses assumptions - Management provided insights into the dynamics affecting gross margin, including higher trade-ins and the mix of da Vinci 5 systems [64][66] Question: Competition in China - Management acknowledged increased competition in China but expressed confidence in their ability to compete effectively with local robotic companies [68][70]

Financial Data and Key Metrics Changes - Revenue grew 21% year over year to $10.1 billion, with operating margins at 37% reflecting investments in R&D and manufacturing scale [7][15][27] - Proforma EPS increased 22%, marking the third consecutive year of growth above 20% [15] - Free cash flow rose to $2.5 billion from $1.3 billion in 2024, driven by increased profitability and lower capital expenditures [15] Business Line Data and Key Metrics Changes - Total procedures grew 19%, with da Vinci procedures increasing 17% and Ion procedures growing 51% [5][14] - In Q4, da Vinci procedures grew 18%, with general surgery in the U.S. and broad-based growth in international markets driving this increase [15][17] - The installed base of da Vinci systems increased by 12% to over 11,100 systems, while average system utilization rose by 4% [16] Market Data and Key Metrics Changes - U.S. da Vinci procedures increased 15% to over 2 million, while international procedures grew by 23% to over 1.1 million [5][19] - Growth rates were 21% in Europe, 24% in Asia, and 27% in the rest of the world [5] - In Q4, total procedures outside the U.S. grew 22%, with notable increases in Canada, India, Korea, and distributor markets [19] Company Strategy and Development Direction - The company focuses on four strategic priorities: launching da Vinci 5, increasing adoption of focused procedures, building industrial scale and product quality, and enhancing digital tools [4][5] - Plans to expand the da Vinci XIR system and related economic programs to increase access to da Vinci surgery internationally and in U.S. ambulatory surgery centers [7][11] - Continued investment in market access activities and local evidence generation to meet clinical and economic objectives [6] Management's Comments on Operating Environment and Future Outlook - Management believes the company is in the early stages of advancing minimally invasive care, with significant long-term opportunities ahead [4][5] - Anticipated full-year da Vinci procedure growth for 2026 is projected to be between 13%-15%, driven by general surgery in the U.S. and international procedures [32] - The company expects gross profit margins to be within a range of 67%-68% of net revenue for 2026, with potential impacts from tariffs and product mix [33] Other Important Information - The company received FDA clearance for several cardiac procedures on da Vinci 5, with plans for a measured rollout to support training and adoption [8][36] - The My Intuitive Plus digital subscription package is expected to enhance customer engagement and provide additional revenue streams starting in 2026 [55] Q&A Session Summary Question: About FDA approvals for cardiac non-force feedback instruments - Management discussed ongoing support for cardiac surgery and the importance of training pathways and developing specific instrumentation for cardiac procedures [36][37] Question: Expanding footprint in ASCs - Management highlighted the growing opportunity in ASCs for lower acuity procedures and the need for high-quality clinical outcomes and operational infrastructure [41][42] Question: Gross margin and operating expenses assumptions - Management explained the dynamics affecting gross margin, including higher trade-ins and the mix of da Vinci 5 systems, while also addressing operating expense growth expectations [46][47] Question: Position in China and competition - Management acknowledged increased competition in China but expressed confidence in their ability to compete effectively with local robotic companies [49][50]

Financial Data and Key Metrics Changes - CSX reported a modest total volume growth of 1% in the fourth quarter, but revenue decreased by 1% due to business mix headwinds and coal pricing [7][12] - Operating income fell by 9% and earnings per share decreased by 7% year-over-year, with results impacted by approximately $50 million in expenses related to workforce optimization and technology impairments [3][8] - Fourth quarter expenses increased by $73 million, or 3%, excluding goodwill impairment charges, with a focus on driving efficiency in labor costs [9][10] Business Line Data and Key Metrics Changes - Merchandise volume and revenue both declined by 2%, with significant softness in chemicals and forest products, where volumes dropped by 6% and 11% respectively [13] - The intermodal franchise saw revenue growth of 7% year-over-year, driven by a 5% increase in volume, indicating strong performance in this segment [14] - Coal business volume increased by 1% year-over-year, with domestic tonnage up by 6% due to rising power demand and higher natural gas prices, while export tonnage declined by 3% [14][15] Market Data and Key Metrics Changes - The industrial chemicals market remains weak, and many customers are controlling freight spending due to inflation and tariff pressures [13] - The housing market is expected to see a modest decline in starts, impacting the automotive market and overall commodity demand [16] - Infrastructure project activity is driving demand for materials such as cement and aggregates, which is a positive for CSX's merchandise volumes [16] Company Strategy and Development Direction - CSX is focused on delivering stronger performance through cost structure adjustments and operational efficiencies, aiming for year-over-year operating margin expansion of 200-300 basis points in 2026 [20][21] - The company plans to maintain capital expenditures below $2.4 billion, prioritizing investments in safety, reliability, and growth projects [21] - CSX is preparing for potential opportunities arising from industry mergers while emphasizing the importance of running the business effectively in the interim [50][51] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a challenging year with subdued demand and limited growth opportunities, but remains committed to improving service levels and operational efficiency [3][4] - The near-term outlook for key markets remains soft, with expectations of low single-digit revenue growth based on flat industrial production and modest GDP growth [20] - Management is optimistic about the potential for growth in 2026, particularly in intermodal and domestic utility segments, despite ongoing market uncertainties [18][19] Other Important Information - The company has identified over 100 diverse savings initiatives aimed at reducing non-labor spending and improving operational efficiency [10][46] - CSX is focused on enhancing its pricing strategies to ensure pricing growth exceeds cost inflation in 2026 [25][26] Q&A Session Summary Question: What is the base operating ratio for 2025 and how does pricing compare to cost inflation? - The base operating ratio for 2025 excludes goodwill charges, and management is optimistic about achieving pricing above cost inflation in 2026 through new pricing structures [25][26] Question: Can you provide details on the 200-300 basis point guidance for improvement? - The guidance includes unique charges from 2025, and management expects significant productivity improvements driven by cost optimization initiatives [29][30] Question: What are the expectations for revenue growth in 2026? - Revenue growth is expected to be low single-digit, with modest volume growth anticipated, influenced by market conditions and pricing strategies [33][34] Question: How is CSX preparing for upcoming storms and operational challenges? - CSX is better prepared for storms this year, with improved network conditions and proactive measures in place to mitigate disruptions [38][39] Question: How is the company positioning itself amid industry mergers? - CSX is focused on running the business effectively while preparing for potential opportunities arising from industry consolidation [50][51] Question: What is the outlook for coal revenue per unit (RPU)? - Coal RPU is expected to stabilize, with a mix of lower RPU segments impacting overall revenue growth [54][57]

Old Republic International (NYSE:ORI) Q4 2025 Earnings call January 22, 2026 03:00 PM ET Company ParticipantsJoe Calabrese - Head of Investor RelationsCraig R. Smiddy - President and CEOCarolyn Monroe - CEOFrank Sodaro - CFOConference Call ParticipantsPaul Newsome - Managing Director and Equity Research AnalystGregory Peters - Managing Director and Equity Research AnalystOperatorHello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like ...

Financial Data and Key Metrics Changes - For Q4 2025, the company reported net income of $16.3 million or $1.45 per diluted common share, an increase from $14.9 million or $1.27 per diluted common share in Q4 2024 [3][10] - Full-year net income for 2025 totaled $71 million or $6.19 per diluted common share, up from $61.8 million or $5.26 per diluted common share in 2024 [10][18] - Net interest income for Q4 2025 was $49.2 million, a slight decrease of $371,000 or 0.7% compared to Q4 2024 [4][11] - Non-interest income increased to $7.2 million in Q4 2025 from $6.9 million in Q4 2024 [13][14] - Non-interest expense decreased to $36 million in Q4 2025, down 2.6% from $36.9 million in Q4 2024 [8][14] Business Line Data and Key Metrics Changes - Net loans receivable at year-end totaled $4.336 billion, a decline of $333.5 million or 7.1% from the previous year, primarily due to elevated payoff activity [5][16] - Total deposits decreased by $122.8 million or 2.7% to $4.48 billion at year-end 2025, driven by a decline in brokered deposits [6][17] - Core deposits remained stable, with a notable increase in interest-bearing checking accounts by $75 million [7][17] Market Data and Key Metrics Changes - Non-performing assets represented 0.15% of total assets at year-end, consistent with both the linked quarter and prior year quarter [7][17] - The company maintained strong liquidity with cash and cash equivalents totaling $189.6 million and access to approximately $1.63 billion in additional borrowing capacity [16][18] Company Strategy and Development Direction - The company remains focused on preserving net interest margins, protecting credit quality, controlling non-interest expenses, and opportunistically repurchasing stock [3][9] - The management emphasized a conservative underwriting posture and maintaining strong capital and liquidity levels to navigate economic challenges [9][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in loan growth due to elevated payoffs but expressed confidence in the strength of their loan portfolio and ongoing efforts to originate new loans [30][39] - The company does not expect significant changes in net interest margins in the near term, with a slight bias towards potential increases depending on market conditions [28][29] Other Important Information - Stockholders' equity increased to $636.1 million at year-end 2025, representing 11.4% of total assets, with a book value per common share of $57.50 [18][19] - The board declared a regular quarterly cash dividend of $0.43 per common share, consistent with the previous quarter [20] Q&A Session Summary Question: Margin outlook for 2026 - Management noted that they performed better than expected in Q4 2025, managing funding costs effectively, but did not anticipate significant margin increases moving forward [24][25][28] Question: Loan growth expectations - Management indicated that loan growth would remain challenging due to ongoing payoffs, but they are actively generating new loans [30][32][39] Question: Expense expectations for 2026 - Management acknowledged that expenses may increase due to annual salary adjustments and payroll tax resets [33]

Old Republic International (NYSE:ORI) Q4 2025 Earnings call January 22, 2026 03:00 PM ET Company ParticipantsJoe Calabrese - Head of Investor RelationsCraig R. Smiddy - President and CEOCarolyn Monroe - CEOFrank Sodaro - CFOConference Call ParticipantsPaul Newsome - Managing Director and Equity Research AnalystGregory Peters - Managing Director and Equity Research AnalystOperatorHello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like ...

Financial Data and Key Metrics Changes - In Q4 2025, the company reported consolidated pre-tax operating income of $236 million, down from $285 million in Q4 2024, with a consolidated combined ratio of 96% compared to 92.7% [4] - For the full year 2025, consolidated pre-tax operating income was $1 billion, with a combined ratio of 94.7% [4] - The operating return on beginning equity was 14.1%, and book value per share increased by 22% [4][10] Business Line Data and Key Metrics Changes - Specialty insurance net premiums earned grew by 8.3% in Q4 2025 and by 10.9% for the full year, surpassing $5 billion for the first time [5] - Specialty insurance pre-tax operating income for Q4 was $178 million, down from $228 million, with a combined ratio of 97.3 compared to 91.8 [5] - Title insurance premiums and fees increased by 12.4% in Q4 2025, with pre-tax operating income rising to $65 million from $55.4 million [5][19] Market Data and Key Metrics Changes - The commercial sector showed strong activity, while the residential market faced challenges due to pricing and affordability issues [17] - Commercial premiums accounted for 29% of earned premiums in Q4 2025, up from 23% in the same quarter last year [17] Company Strategy and Development Direction - The company aims to maintain pricing discipline and underwriting excellence, focusing on profitability over top-line growth [25] - Investments in technology modernization, data analytics, and AI are expected to yield long-term benefits despite short-term expense ratio pressures [12] - The specialty portfolio is now more diversified, which positions the company to manage market cycles effectively [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving consistent performance in 2026, despite potential pricing pressures in the market [25] - The company anticipates solid growth and profitability in specialty insurance, driven by contributions from new specialty operating companies [16] Other Important Information - The company declared nearly $700 million in dividends and repurchased $56 million worth of shares, totaling over $1 billion in capital returns for the year [10] - There is $850 million remaining in the current share repurchase program, with plans to utilize it opportunistically [59] Q&A Session Summary Question: What are the combined ratio targets for 2026? - Management expects to maintain a combined ratio around 93.2 for 2026, with variations depending on the operating company [24] Question: What led to the higher loss pick in commercial auto? - Management noted that while paid claims did not reflect changes, case reserves increased, prompting a conservative approach to loss picks [26][28] Question: What is the outlook for the title business in 2026? - The title business is expected to see a 15%-20% improvement in commercial premiums, while residential premiums may see single-digit growth [34] Question: Are there geographic patterns in case reserves? - No significant geographic patterns were detected, but an increase in bodily injury claims and litigation was noted [45][46] Question: How does the company plan to react to loss trend changes? - The company will continue to adjust rates conservatively based on observed trends, focusing on risk selection and targeted rate increases [49][52]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported net income of $16.3 million or $1.45 per diluted common share, an increase from $14.9 million or $1.27 per diluted common share in Q4 2024 [3][10] - Full-year net income for 2025 totaled $71 million or $6.19 per diluted common share, up from $61.8 million or $5.26 per diluted common share in 2024 [10][18] - Net interest income for Q4 2025 was $49.2 million, a slight decrease of $371,000 or 0.7% compared to the prior year quarter [4][11] - The efficiency ratio improved to 63.89% in Q4 2025 from 65.43% in Q4 2024 [15] Business Line Data and Key Metrics Changes - Net loans receivable decreased to $4.336 billion at year-end, down $333.5 million or 7.1% from the previous year, with declines in multifamily residential, commercial construction, and commercial business loans [5][16] - Total deposits decreased by $122.8 million or 2.7% to $4.48 billion, primarily due to a decline in brokered deposits [16][17] - Non-interest income increased to $7.2 million in Q4 2025 from $6.9 million in Q4 2024, driven by higher late charges and fees [12][13] Market Data and Key Metrics Changes - Non-performing assets represented 0.15% of total assets at year-end, consistent with both the linked quarter and prior year quarter [7][17] - The company maintained strong liquidity with cash and cash equivalents totaling $189.6 million and access to approximately $1.63 billion of additional borrowing capacity [16] Company Strategy and Development Direction - The company remains focused on preserving net interest margins, protecting credit quality, controlling non-interest expenses, and opportunistically repurchasing stock [3][9] - Management emphasized a conservative underwriting posture and a focus on pricing, structure, and borrower stream to navigate economic pressures [5][9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that loan growth may remain challenging due to elevated payoffs and competitive market conditions, but expressed confidence in the company's conservative approach and sound balance sheet management [9][30] - The company did not record a provision for credit losses on outstanding loans in 2025, reflecting stable borrower performance [18] Other Important Information - Stockholders' equity increased to $636.1 million at year-end 2025, representing 11.4% of total assets, with a book value per common share of $57.50 [18][19] - The board declared a regular quarterly cash dividend of $0.43 per common share, consistent with the previous quarter [20] Q&A Session Summary Question: Regarding the margin and its outlook for 2026 - Management noted that they performed better than expected in Q4 2025, managing funding costs proactively and seeing some loans redeployed at higher rates [25][26] Question: Expectations for loan growth and payoffs - Management indicated that loan growth would remain challenging, with good activity but elevated payoffs continuing to impact net growth [30][31] Question: Future expenses and potential increases - Management acknowledged that there would likely be an uptick in expenses due to annual increases in salaries and benefits [35]